PROVECTUS BIOPHARMACEUTICALS, INC.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

Provectus Biopharmaceuticals, Inc.

(Name of registrant as specified in its charter)

(Name of person(s) filing proxy statement, if other than the registrant)

Payment of Filing Fee (Check the appropriate box):

800 S. Gay Street, Suite 1610 Knoxville, Tennessee 37929 phone 866/594-5999 fax 866/998-0005

Dear Provectus Stockholder:

You are cordially invited to attend the 2026 Annual Meeting of Stockholders of Provectus Biopharmaceuticals, Inc. (“Provectus”) on Thursday, June 18, 2026 at Perkins Place Office Building located at 525 Portland Street, Knoxville, Tennessee 37919, beginning at 4:00 p.m. Eastern Time (the “2026 Annual Meeting”). We intend to hold our annual meeting in person. As always, we encourage you to vote your shares prior to the meeting.

We are pleased to present you with our 2026 Proxy Statement. At our 2026 Annual Meeting, stockholders will vote on the matters set forth in the 2026 Proxy Statement and the accompanying notice of this meeting. Your board of directors (the “Board”) has recommended four highly qualified and experienced nominees for election to Provectus’s Board at the 2026 Annual Meeting. Highlights of the detailed information included in the Proxy Statement may be found in the section entitled “Questions and Answers About the 2026 Annual Meeting of Stockholders,” starting on page 2. Detailed information regarding director candidates may be found under “Proposal 1 – Election of Directors,” starting on page 19.

We are providing access to our proxy materials over the Internet under the U.S. Securities and Exchange Commission’s “notice and access” rules. We believe that providing our proxy materials electronically increases the ability of our stockholders to connect with information they need, while reducing the costs and environmental impact associated with printing and mailing of proxy materials.

Whether you will attend the 2026 Annual Meeting or not, we hope that your shares are represented and voted. In advance of the meeting on June 18, 2026, please vote and submit your proxy as soon as possible via the Internet, by telephone, or, if you have requested to receive printed proxy materials, by mailing the proxy or voting instruction card enclosed with those materials. Instructions on how to vote are found in the section entitled “Questions and Answers About the 2026 Annual Meeting of Stockholders – How do I vote before the Annual Meeting?” starting on page 4.

For more information and up-to-date postings, please visit www.provectusbio.com/annual-meeting.

Thank you for being a Provectus stockholder.

Sincerely,

/s/ Dominic Rodrigues

Dominic Rodrigues

President

800 S. Gay Street, Suite 1610 Knoxville, Tennessee 37929 phone 866/594-5999 fax 866/998-0005

NOTICE OF 2026 ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD ON THURSDAY, JUNE 18, 2026

To the Stockholders of Provectus Biopharmaceuticals, Inc.:

NOTICE IS HEREBY GIVEN that we will hold the 2026 Annual Meeting of Stockholders of Provectus Biopharmaceuticals, Inc. on Thursday, June 18, 2026, at Perkins Place Office Building located at 525 Portland Street, Knoxville, Tennessee 37919 beginning at 4:00 p.m. Eastern Time. As always, we encourage you to vote your shares prior to the meeting.

The 2026 Annual Meeting is being held for the following purposes:

Stockholders also would transact any other business that properly comes before the 2026 Annual Meeting.

OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” EACH OF THE FOUR DIRECTOR NOMINEES WHO ARE IDENTIFIED IN THE PROXY STATEMENT, AND “FOR” EACH OF PROPOSALS 2, 3, 4, and 5.

Only stockholders of record as of the close of business on April 20, 2026, will be entitled to notice of and to vote at the 2026 Annual Meeting of Stockholders and any adjournment thereof.

We are mailing a Notice of Internet Availability of Proxy Materials (the “Notice”) to our stockholders instead of paper copies of our proxy statement and annual report. The Notice contains instructions for accessing those documents over the Internet. The Notice also contains instructions on how stockholders can receive a paper copy of our proxy materials, including the proxy statement, our 2026 Annual Report, and the proxy card.

We hope that you will be able to attend the 2026 Annual Meeting. Whether or not you plan to attend the meeting, we ask that you vote as soon as possible. Prompt voting helps to ensure that the greatest number of stockholders are present, whether in person or by proxy. You may vote over the Internet, by telephone, or, if you requested to receive printed proxy materials, by mailing the proxy or voting instruction card enclosed with these meeting materials. Please review the instructions for each of your voting options described in the proxy statement, as well as in the Notice you received in the mail.

If you attend the 2026 Annual Meeting in person, you may revoke your proxy at the meeting and vote your shares in person. You may revoke your proxy at any time before the proxy is exercised. Should you desire to revoke your proxy, you may do so as provided in the accompanying proxy statement.

Important Notice Regarding the Availability of Proxy Materials for the 2026 Annual Meeting of Stockholders to Be Held on Thursday, June 18, 2026. The Notice of Internet Availability of Proxy Materials, this Proxy Statement and our Annual Report on Form 10-K for the year ended December 31, 2025 are available at www.proxyvote.com.

By order of our board of directors,

/s/ Dominic Rodrigues

Dominic Rodrigues

President

April 30, 2026

Knoxville, Tennessee

TABLE OF CONTENTS

i

800 S. Gay Street, Suite 1610 Knoxville, Tennessee 37929 phone 866/594-5999 fax 866/998-0005

PROXY STATEMENT FOR

2026 ANNUAL MEETING OF STOCKHOLDERS

TO BE HELD ON JUNE 18, 2026

We are delivering these proxy materials to solicit proxies on behalf of the board of directors of Provectus Biopharmaceuticals, Inc., for the 2026 Annual Meeting of Stockholders that will be held on Thursday, June 18, 2026, at Perkins Place Office Building located at 525 Portland Street, Knoxville, Tennessee 37919, beginning at 4:00 p.m. Eastern Time. We intend to hold our 2026 Annual Meeting in person. Please monitor our meeting website at www.provectusbio.com for updated information. If you are planning to attend our meeting, please check the website one week prior to the meeting date. As always, we encourage you to vote your shares prior to the meeting.

We will mail the Notice of Internet Availability of Proxy Materials to our stockholders on or about May 8, 2026.

We will refer to Provectus Biopharmaceuticals, Inc. and its subsidiaries throughout this Proxy Statement as “we,” “us,” the “Company,” or “Provectus.” We will refer to the board of directors as the “Board” or “our Board.”

At the 2026 Annual Meeting, our stockholders will vote on five proposals:

The proposals are set forth in the accompanying Notice of 2026 Annual Meeting of Stockholders and are described in more detail in this Proxy Statement. Stockholders also may transact any other business not known or determined at the time of this proxy solicitation and that properly comes before the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”); however, our Board knows of no such other business.

OUR BOARD UNANIMOUSLY RECOMMENDS THAT YOU VOTE “FOR” EACH OF THE FOUR BOARD NOMINEES WHO ARE IDENTIFIED IN THE PROXY STATEMENT, AND “FOR” EACH OF PROPOSALS 2, 3, 4, and 5.

When you submit your proxy, by executing and returning the enclosed proxy card, you will authorize proxy holders Dominic Rodrigues, President and Heather Raines, CPA, Chief Financial Officer, to vote all your shares of common stock and/or preferred stock and otherwise to act on your behalf at the 2026 Annual Meeting and any adjournment thereof, in accordance with the instructions set forth therein. These persons also will have discretionary authority to vote your shares on any other business that properly comes before the 2026 Annual Meeting. They also may vote your shares to adjourn the 2026 Annual Meeting and will be authorized to vote your shares at any meeting adjournment.